Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing ...
Pharmaceutical Technology on MSN
FDA increases manufacturing flexibility for cell and gene therapies
Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.
FOSHAN, GUANGDONG, CHINA, January 12, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback